You are here

Astellas

Astellas reports data from Phase IIIb trial to treat VMS due to menopause

Clinical Trials Arena

Wed, 06/28/23 - 09:58 am

clinical trials

Mimetas and Astellas expand partnership to include automation and application support

Biopharma Reporter

Tue, 06/27/23 - 10:27 pm

organ-on-a-chip

Astellas delves deeper into protein degrading drugs with Cullgen deal

BioPharma Dive

Thu, 06/15/23 - 09:55 am

protein degradation

With Iveric Bio buyout, Astellas CEO Okamura acted on the company's mantra to be 'aggressive'

Fierce Pharma

Tue, 06/13/23 - 10:43 am

Astellas hit by US patent verdict for incontinence drug

Pharmaphorum

Mon, 06/12/23 - 10:23 am

urinary incontinence

Astellas Partners with Kate Therapeutics in Gene Therapy, After Four Patient Deaths in Previous Trials

BioSpace

Thu, 06/8/23 - 09:54 am

Kate Therapeutics

X-linked myotubular myopathy

Bayer, Amgen looked at Iveric before agreeing to Astellas sale

Seeking Alpha

Tue, 05/23/23 - 06:20 pm

Heightened US antitrust fears rattle biopharma

EP Vantage

Wed, 05/17/23 - 10:12 am

Horizon Therapeutics

Prometheus Biosciences

Astellas, Sony Team on Novel ADC Platform for Oncology

BioSpace

Tue, 05/16/23 - 12:20 pm

Sony Corporation

antibody-drug conjugate

Astellas' Menopause Drug Scores FDA Approval, After Regulatory Setback

Yahoo/Benzinga

Mon, 05/15/23 - 11:21 am

Astellas to acquire eye drug developer Iveric Bio for $5.9B

BioPharma Dive

Mon, 05/1/23 - 11:13 am

Pfizer, Astellas' Xtandi combo cuts risk of death by 58% in prostate cancer patients

Seeking Alpha

Mon, 05/1/23 - 10:13 am

prostate cancer

clinical trials

FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market

Fierce Biotech

Fri, 04/21/23 - 10:08 am

Twist Bioscience Enters into Third Collaboration with Astellas to Support Antibody Discovery for Immunotherapies

Businesswire

Thu, 04/20/23 - 11:56 am

Twist Bioscience

drug development

FDA Approves Keytruda/Padcev Combo in Advanced Urothelial Cancer

BioSpace

Tue, 04/4/23 - 12:35 pm

metastatic urothelial carcinoma

Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy

CP Wire

Sun, 03/26/23 - 03:44 pm

PTC Therapeutics

Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy

Sun, 03/26/23 - 03:36 pm

PTC Therapeutics

Pages